Clinical Metabolomics Applications in Genetic Diseases

Dr. Anas M. Abdel Rahman is an accomplished clinical scientist at the Metabolomics Section in the Department of Clinical Genomics at King Faisal Specialist Hospital and Research Center (KFSHRC)’s Center for Genome Medicine (CGM), and and Associate Professor at the Department of Biochemistry and Molecular Medicine in Alfaisal University’s School of Medicine, Saudi Arabia. He holds a Ph.D. in Bioanalytical Chemistry from the Memorial University of Newfoundland (NL, Canada).  With over a decade of experience in metabolomics research, Dr. Abdel Rahman's research has been focused on the next generation of metabolic screening. He has been actively involved in studying rare genetic diseases using advanced omics techniques, including metabolomics. His research group has successfully established metabolomics platforms for biomarker discovery and disease prediction models.  Dr. Abdel Rahman's research has led to numerous publications in high-impact scientificjournals, and his contributions to the field of clinical metabolomics have been widely recognized. He is a respected mentor, inspiring the next generation of researchers and scientists and advancing the field of personalized medicine. 

lt;p>Chapter 1. The advanced technology and clinical application in metabolomics.- Chapter 2. Mass Spectrometry-Based Metabolomics for the Clinical Laboratory.- Chapter 3. Metabolomics: a pipeline for biomarker discovery in genetic diseases.- Chapter 4. Bioinformatics Tools for Clinical Metabolomics.- Chapter 5. Untargeted Metabolomics in Newborn Screening.- Chapter 6. Untargeted Metabolomics, Targeted Care: The Clinical Utilities of Bedside Metabolomics.- Chapter 7. Metabolomics in the Study of Human Mitochondrial Diseases.- Chapter 8. Metabolomics of Rare endocrine, genetic disease- A focus on the Pituitary gland.- Chapter 9. Metabolomics and genetics of rare endocrine disease - adrenal, parathyroid glands, and cystic fibrosis.- Chapter 10. Metabolomics role in personalized medicine: An update.- Chapter 11. Lipidomic Profiling in Clinical Practice Using LC-MS.- Chapter 12. Bringing Human Serum Lipidomics to the Forefront of Clinical Practice: Two Clinical Diagnosis Success Stories.- Chapter 13. LC-MS based population metabolomics: a mini-review of recent studies and challenges from sample collection to data processing.- Chapter 14. Metabolomics and transcriptomics approach to understand the pathophysiology of interstitial lung disease.- Chapter 15. Transferring metabolomics to portable diagnostic devices- Trending in biosensors.